Ally Bridge Group »

Black Diamond Therapeutics shares owned by Ally Bridge Group

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Ally Bridge Group from 13F filings

Historical chart of Ally Bridge Group investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Ally Bridge Group

Quarter filed Position value Share count Share price at filing
2023-09-30 $1.8M 634k 2.87
2023-06-30 $4.0M 800k 5.05

More positions owned by Ally Bridge Group

Moonlake Immunotherapeutics Class A Ord (MLTX)
Xenon Pharmaceuticals (XENE)
Intra Cellular Therapies (ITCI)
Axsome Therapeutics (AXSM)
Apellis Pharmaceuticals (APLS)
Cytokinetics Com New (CYTK)
Merus N V (MRUS)
Amylyx Pharmaceuticals (AMLX)
Geron Corporation (GERN)
Ardelyx (ARDX)
Ambrx Biopharma Sponsored Ads
Mirati Therapeutics
Jasper Therapeutics
Black Diamond Therapeutics (BDTX)
Praxis Precision Medicines I

View all positions for Ally Bridge Group

Top funds holding Black Diamond Therapeutics

Bellevue Group
NEA Management Company
RA Capital Management
Artal Group
Vanguard Group
Tang Capital Management
Jpmorgan Chase & Co
Kennedy Capital Management
Blue Owl Capital Holdings
Ikarian Capital
Candriam Luxembourg S.C.A.
Boxer Capital
Two Sigma Investments
Newtyn Management
Barclays

View all funds holding Black Diamond Therapeutics